Full Library

Return to list of results

CD19, CD20 and CD52

RIS

Recommended format for most reference management software

BibTeX

Recommended format for BibTeX-specific software

Open in Zotero
View on zotero.org
Resource type
Book Section
Authors/contributors
Title
CD19, CD20 and CD52
Abstract
Agents targeting the CD19, CD20 and CD52 surface antigens on lymphoid cells have been increasingly used in the past three decades in various haematologic, rheumatologic and autoimmune diseases. The impact these agents have on the immune system and their consequent infectious complications depend on the agent, dose, underlying disease and concomitant or previous immunosuppressive treatments.
Book Title
Infectious Complications in Biologic and Targeted Therapies
Date
2022
Publisher
Springer International Publishing
Place
Cham
Pages
113-151
ISBN
978-3-031-11363-5
URL
https://doi.org/10.1007/978-3-031-11363-5_7
Accessed
11/27/22, 5:23 PM
Language
en
Library Catalog
Springer Link
Extra
DOI: 10.1007/978-3-031-11363-5_7
Citation
Mikulska, M., & Averbuch, D. (2022). CD19, CD20 and CD52. In C. Cervera & J. M. Aguado (Eds.), Infectious Complications in Biologic and Targeted Therapies (pp. 113–151). Springer International Publishing. https://doi.org/10.1007/978-3-031-11363-5_7
HEME-ONC AND CELLULAR THERAPIES
Link to this record
https://www.transplantid.net/8JLGT5MF